Literature DB >> 31406976

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

G V Long, K T Flaherty, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, C Garbe, T Jouary, A Hauschild, V Chiarion-Sileni, C Lebbe, M Mandalá, M Millward, A Arance, I Bondarenko, J B A G Haanen, J Hansson, J Utikal, V Ferraresi, P Mohr, V Probachai, D Schadendorf, P Nathan, C Robert, A Ribas, M A Davies, S R Lane, J J Legos, B Mookerjee, J-J Grob.   

Abstract

Entities:  

Year:  2019        PMID： 31406976      PMCID： PMC6927319          DOI： 10.1093/annonc/mdz221

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
Ann Oncol 2017; 28(7): 1631–1639 (doi: 10.1093/annonc/mdx176) The following funding information has been added: “This work was supported in part by The University of Texas MD Anderson Cancer Center Support Grant P30 CA016672.”
  8 in total

1.  Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.

Authors:  Dimitrios C Ziogas; Frosso Konstantinou; Spyros Bouros; Maria Theochari; Helen Gogas
Journal:  Am J Clin Dermatol       Date:  2021-03-25       Impact factor: 7.403

2.  Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients.

Authors:  Paweł Rogala; Anna M Czarnecka; Bożena Cybulska-Stopa; Krzysztof Ostaszewski; Karolina Piejko; Marcin Ziętek; Robert Dziura; Ewa Rutkowska; Łukasz Galus; Natasza Kempa-Kamińska; Joanna Seredyńska; Wiesław Bal; Katarzyna Kozak; Anna Surus-Hyla; Tomasz Kubiatowski; Grażyna Kamińska-Winciorek; Rafał Suwiński; Jacek Mackiewicz; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2022-04-24       Impact factor: 6.575

3.  Correlation between initial tumour volume and treatment duration on Dabrafenib: observation study of subjects with BRAF mutant melanoma on the BRF112680 trial.

Authors:  Arwa Ali; Monica Dumbrava; Kylie Riddell; Nina Stewart; Robyn Ward; Ahmed K Ibrahim; Melvin Chin
Journal:  BMC Cancer       Date:  2020-04-22       Impact factor: 4.430

Review 4.  Cellular Reprogramming-A Model for Melanoma Cellular Plasticity.

Authors:  Karol Granados; Juliane Poelchen; Daniel Novak; Jochen Utikal
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

5.  Long-term control of melanoma brain metastases with co-occurring intracranial infection and involuntary drug reduction during COVID-19 pandemic: A case report.

Authors:  Yang Wang; Bin Lian; Chuan-Liang Cui
Journal:  World J Clin Cases       Date:  2021-04-06       Impact factor: 1.337

6.  Focal adhesion kinase plays a dual role in TRAIL resistance and metastatic outgrowth of malignant melanoma.

Authors:  Greta Del Mistro; Shamala Riemann; Sebastian Schindler; Stefan Beissert; Roland E Kontermann; Aurelien Ginolhac; Rashi Halder; Luana Presta; Lasse Sinkkonen; Thomas Sauter; Dagmar Kulms
Journal:  Cell Death Dis       Date:  2022-01-12       Impact factor: 8.469

7.  Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection.

Authors:  Kristy K Broman; Deepti Bettampadi; Jaileene Pérez-Morales; James Sun; Dennis Kirichenko; Michael J Carr; Zeynep Eroglu; Ahmad A Tarhini; Nikhil Khushalani; Matthew B Schabath; Amod Sarnaik; Vernon K Sondak; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2021-08-06       Impact factor: 5.344

Review 8.  Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer.

Authors:  Tanner Fullmer; Maria E Cabanillas; Mark Zafereo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-15       Impact factor: 5.555
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.